Clinical Scorecard: Overexpression of Glucagon-like Peptide-1 Receptor (GLP-1R) Identifies a Unique Immunogenetic Group in Primary and Metastatic Thyroid Carcinoma: Consequences for GLP-1R Agonist Treatment
At a Glance
Category
Detail
Condition
Key Mechanisms
GLP-1R expression and its association with immune pathway activity and cell proliferation.
Target Population
Care Setting
Key Highlights
Metastatic papillary thyroid carcinoma (PTC) shows the highest GLP-1R mRNA expression among all TCGA cancers.
GLP-1R expression stratifies thyroid cancers into unique immunogenetic profiles.
Guideline-Based Recommendations
Diagnosis
Monitor GLP-1R expression levels in thyroid carcinoma patients.
Management
Monitoring & Follow-up
Regularly assess thyroid cancer patients for potential development of medullary thyroid carcinoma (MTC) when on GLP-1 RAs.
Risks
Increased risk of MTC associated with prolonged use of GLP-1 RAs.
Patient & Prescribing Data
Adults with Type-2 Diabetes Mellitus and/or obesity.
GLP-1 RAs are prescribed for diabetes management and weight loss, but carry risks for thyroid carcinoma.
